Keyphrases
Type 2 Diabetic Patients
100%
Type 2 Diabetes Mellitus (T2DM)
82%
Placebo
70%
Metformin
70%
Bolus Calculation
66%
Type I Diabetes
66%
Type 1 Diabetes Mellitus (T1DM)
66%
Multiple Daily Insulin Injections
66%
Insulin Analogues
53%
Intermittently Scanned Continuous Glucose Monitoring (isCGM)
50%
Insulin Therapy
42%
Hemoglobin A1c (HbA1c)
37%
Randomized Placebo-controlled Trial
37%
Copenhagen
36%
Metformin Therapy
36%
Insulin
36%
Multicenter Trial
34%
Flash Glucose Monitoring
33%
Randomized Controlled Trial
33%
Weight Gain
27%
Insulin Dose
25%
Carotid Intima-media Thickness (cIMT)
25%
Insulin-treated
20%
Carbohydrate Counting
19%
Sulfonylurea
16%
Whole-body Composition
16%
Bone Mineral Density
16%
Trabecular Bone Score
16%
GLP-1 Receptor Agonist
16%
Footnotes
16%
KCNJ11
16%
Excessive Weight Gain
16%
Neonatal Diabetes
16%
Add-on Therapy
16%
Usual Care
16%
Bone Turnover Markers
16%
Basal Insulin
16%
Overweight Patient
16%
Procollagen Type 1 N-terminal Propeptide (P1NP)
16%
Detemir
16%
Glycemic Control
16%
Bone Mineral Content
14%
Treatment Satisfaction
11%
Between-group Difference
10%
Body Composition
10%
Monotherapy
10%
Bolus Calculator
9%
Body Mass Index
9%
Time in Range
8%
Serious Adverse Events
8%
Medicine and Dentistry
Patient with Type 2 Diabetes
100%
Maturity Onset Diabetes of the Young
89%
Glycon
87%
Placebo
77%
Insulin Derivative
70%
Hemoglobin A1c
69%
Insulin Dependent Diabetes Mellitus
66%
Flushing
37%
Randomized Controlled Trial
33%
Diabetes
31%
Intima-Media Thickness
24%
Carbohydrate Counting
22%
Glycemic Control
19%
Sulfonylurea
16%
Glucagon-Like Peptide-1 Agonist
16%
Obesity
16%
Bone Density
16%
Cancellous Bone
16%
Add on Therapy
16%
Body Mass Index
15%
Arm
15%
Hypoglycemia
13%
Insulin Treatment
11%
Bone Mineral
10%
Adverse Event
10%
Patient-Reported Outcome
9%
Antidiabetic Agent
8%
Monotherapy
8%
Hyperglycemia
8%
Insulin Detemir
6%
Insulin Aspart
6%
Carbetimer
6%
Cardiovascular Disease
5%
Glycated Hemoglobin
5%
Nursing and Health Professions
Metformin
50%
Patient with Type 2 Diabetes
50%
Placebo
40%
Hemoglobin A1c
39%
Diabetes Mellitus
37%
Insulin Derivative
33%
Insulin Dependent Diabetes Mellitus
33%
Continuous Glucose Monitoring
33%
Arterial Wall Thickness
24%
Body Composition
16%
Obesity
16%
Adverse Event
10%
Antidiabetic Agent
8%
Non Insulin Dependent Diabetes Mellitus
6%
Insulin Detemir
6%
Insulin Aspart
6%
Carbetimer
6%
Hypoglycemia
5%
Factorial Design
5%
Cardiovascular Disease
5%
Body Mass
5%
Glycosylated Hemoglobin
5%
Sample Size
5%
